To investigate the impact of an intervention program to improve adherence with topical, once daily therapy for glaucoma.
Adherence to chronic therapy in asymptomatic disease, both for systemic conditions 1 and for glaucoma, 2,3 is less than ideal; repeated documentation has demonstrated that patients take 70% or less of prescribed treatment. Multiple clinical trials have proven that the lowering of intraocular pressure (IOP) slows glaucoma progression. 4, 5 Alternatively, higher IOP is associated with greater incidence and prevalence of openangle glaucoma, as reported in the Barbados Incidence Study of Eye Diseases 6 and the Baltimore Eye Survey. 7 Thus, the authors believe it is logical to assume that poor adherence would be associated with less benefit and worse outcome because IOP is elevated at times when adherence is poor. Developing strategies to improve adherence is an important clinical goal. Adherence with glaucoma eyedrops is suboptimal for many reasons, including situational and environmental factors (e.g., major life events, travel, competing activities, change in routine); medication regimen factors (e.g., refill, cost, complexity, change, adverse events); patient-related factors (e.g., knowledge, memory, motivation and health beliefs, comorbidity); and provider-related factors (e.g., satisfaction with and communication by physicians). 8 Friedman et al 9 identified associations with adherence as measured using a large claims database among patients who also were extensively interviewed. Cost of medication and forgetting while away from home were clear risk factors for poor adherence. In addition, doctor-patient communication and health-related beliefs of patients contributed to patient adherence. Patients who were less concerned about the future effects of glaucoma and the risks of not taking medications had lower adherence. These findings suggest that educational efforts in the office, along with reminder systems, might improve adherence to glaucoma therapy.
There have been many different strategies tested, alone and in combination, to increase patient adherence to medical therapy for chronic conditions. McDonald et al 10 summarized the results of randomized controlled trials (RCTs) on interventions to enhance patient adherence to self-administered medication, finding that successful interventions included more instruction for patients, simplified dosing regimens, added reminders, increased convenience and accessibility to healthcare, rewards for improvement and counseling, and improved patient-provider communication. A more recent major review by Haynes et al 11 summarized RCTs for interventions to improve adherence in several chronic conditions, including hypertension, diabetes, and asthma. Haynes et al reported that effective interventions for chronic conditions almost always addressed multiple potential barriers simultaneously. Many RCTs failed to demonstrate a benefit from intervention.
No RCTs studying adherence to glaucoma medications have been published using medications currently in wide use for patients with glaucoma. In 1979, Norell 12 randomized patients to receive an educational intervention to improve adherence among 82 patients taking pilocarpine eyedrops. Laster et al 13 reported a crossover trial in 13 patients with glaucoma taking pilocarpine using an electronic monitor with an audible reminder. Both studies showed significant improvement with a single intervention over short intervals. We used electronic monitoring of drop-taking to assess a multifaceted program of interventions to improve adherence with topical, once daily glaucoma medication in an RCT.
Materials and Methods

Study Design
Patients were recruited from the Glaucoma Services of the Wilmer Eye Institute and the Scheie Eye Institute. Institutional review boards at both centers approved the study protocol, and written informed consent was obtained from all study patients.
The study had 2 phases. Phase 1 was a prospective, observational cohort study of patient adherence to travoprost therapy for a 3-month interval.
14 Because no other bottles for glaucoma medications fit within the Dosing Aid (DA), it can provide data on use of travoprost only. Travoprost bottles were supplied to those already taking prostaglandin medications or those newly prescribed this class of drug, and patients were instructed in using the DA to administer the drops. The DA both squeezes the drop from the bottle and records the time and date of delivery on an internal, battery-operated chip. We previously reported on the acceptable accuracy of this device for monitoring drop-taking. 15 Patients were aware that the devices recorded their drop-taking.
In phase 2, participants with 75% or fewer administered doses were randomized to either intervention or usual care. The data used for this determination included values obtained during the 8 weeks starting 2 weeks after enrollment and ending 2 weeks before the follow-up visit. Only these data were used because we detected that there was significantly greater adherence just after a visit and just before a visit.
14 A dose was considered taken if the lever of the DA was depressed and recorded Ϯ4 hours from that patient's median dosing hour (as determined from the DA data). Because we recognized from our previous study 15 that the device has the potential to make extra recordings when the lever is depressed erroneously, we did not count more than 1 dose taken per eye per day in our adherence rate calculation. When the lever was depressed outside the time window it was assumed that a dose was not taken, and when the lever was depressed multiple times in the time window only a single dose for 1 or both eyes was assumed to have been delivered.
The intervention consisted of (1) a 10-minute educational video created through Alcon, Inc. (Fort Worth, TX), marketing branch for the DA device, which stressed the importance of regular drop-taking, its rationale and expected effects, alternatives to eyedrops, and methods to maximize cooperation, such as linking drops to a daily activity, keeping a drop-taking calendar diary, and using family members to help in reminding them; (2) a structured discussion with the study coordinator to develop a strategy for improving adherence that included finding the best time of day to take the medication, distributing a blank calendar diary and going over details of how to keep it, and discussing individual patient barriers to taking the medication; (3) reminder telephone calls from the coordinator, including administration of a questionnaire about drop-taking behavior, difficulty with drops, side effects, and eliciting questions about therapy (this call was made once per week for the first follow-up month and then every other week for the next 2 months); and (4) activation of the audible and visible alarms on the DA. Those in the usual care arm ("controls") were told that it is important to take their eyedrops as prescribed but had no other intervention. Participants were randomized using random numbers placed in serially marked, sealed envelopes that were opened at the time of randomization. To perform the randomization procedure, a string of random numbers was selected from a random numbers table. The numbers were placed into envelopes and then sealed and initialed across the seal. The envelopes were numbered consecutively starting with 1. When an eligible patient was identified, an envelope was opened; if the envelope contained an even number then the participant received the intervention.
The target sample size was calculated assuming a mean adherence rate at 75% before intervention. To have 80% power to identify the intervention compliance rate improvement of 20% with a type 1 error of 5%, the target sample size was 49 persons per arm to complete the 3 months of the intervention.
Eligibility Criteria (Both Phases)
Patients had one of the following diagnoses: open-angle glaucoma, angle-closure glaucoma, glaucoma suspect, or ocular hypertension. Patients were 18 years of age or older, using or prescribed a topical prostaglandin analog, and able to return for 3 and 6-month follow-up visits. Some participants had undergone past laser or surgical glaucoma therapy, but not within the 3 months before study enrollment. Patients were excluded if they were unable to understand the study, they did not instill their own drops, or they were incapable of using the DA after a brief demonstration.
Patient Recruitment and Follow-Up
Consenting patients were given sufficient travoprost for the study free of charge and were instructed in using the DA by a study coordinator using an instructional video. All patients were instructed on how to place a bottle of travoprost in the DA and how to depress the lever arm to deliver a drop. Patients practiced using the DAs under supervision before starting the study. Each patient received 1 DA device and was instructed to administer the drops in either 1 or both eyes, depending on his or her ocular diagnosis. Patients were enrolled on days when the study coordinator was available in the clinic.
Patients who were receiving latanoprost or bimatoprost before the study were switched to travoprost. Baseline demographic and medical information were obtained, including age, sex, selfreported ethnicity, home address zip code (to estimate income), presence of comorbid diseases, ocular medications and dosage, systemic medications and dosage, family history of glaucoma, baseline untreated IOP of each eye (if available), length of past glaucoma treatment and types of past ocular medication, including allergies and severe adverse events, and current target IOP of each eye. In addition, data of medications for each eye for the preceding 2 years, the most recent visual fields, and the most recent evaluation of the optic disc by clinical assessment, laser imaging, or photography were also recorded.
Phase 1 patients were instructed to use the devices to deliver their travoprost each night until the 3-month follow-up visit. Patients brought their DA devices to the 3-month visit, the information was downloaded onto computer-based software, the battery was changed, and a questionnaire was administered to evaluate self-reported adherence and satisfaction with the devices. At the 3-month visit, eligible patients for phase 2 were randomized as outlined previously. Also, visual acuity and applanation IOP were measured.
At the 6-month visit, the data from the devices were downloaded, and the intervention and control groups answered a questionnaire about adherence to therapy, side effects, and any change in satisfaction with the devices. Visual acuity and IOP were recorded at the 6-month visit.
Statistical Analysis
Baseline characteristics were compared between the intervention group and the control group. Comparisons for patient-level characteristics were made by Fisher exact test for the comparison of proportions and by the Student t test for the comparison of means. The identification of factors for improved adherence was performed using univariate linear regression models of adherence rate as a continuous variable. The factors associated with PϽ0.10 (treatment group, length of time on glaucoma medication, bilateral use of medication, and institute) or factors of clinical importance (age, race, education, baseline compliance rate, use of travoprost without using the device) were included in the multivariate models. Institute was initially considered but was eventually excluded from the final multivariate model because of its colinearity with the race and education, and the complex interpretation of the resulting results. Patients with missing data in 1 specific variable were excluded from the analysis of this specific variable but were still included in the analysis of other variables without missing data. Statistical analysis was performed by using SAS v9.1 (SAS Inc., Cary, NC).
Results
Study recruitment for the phase 2 randomized trial began in November of 2006 and ended in June of 2007. Of the 66 patients who were adherent less than 75% of the time, 35 (53%) were randomized to the intervention group and 31 (47%) were randomized to the control group. The intervention and control groups were similar in mean age, race, sex, education level, and income based on zip code (PϾ0.05 for all; Table 1 ). The 2 groups also had generally similar ocular characteristics, although the controls were significantly more likely to have used glaucoma drops for 1 year or less (PϽ0.01; Table 2 ).
Adherence to Therapy
The baseline mean adherence in the intervention group was higher than in the control group (54% vs. 46%), but this was not statistically significant (P ϭ 0.10).The mean (Ϯ standard deviation) adherence rate for the intervention group improved to 73Ϯ22% after intervention in phase 2 (PϽ0.01; Table 3 ). By contrast, the control group had no significant change, with 51Ϯ30% in phase 2 (P ϭ 0.19; Table 3 ). The mean adherence rate improvement was 19Ϯ20% in the intervention group and 6Ϯ23% in the control group (P ϭ 0.01 for the difference between the 2 groups; Fig 1) . The mean adherence was higher for every week of follow-up in the intervention group compared with the controls (PϽ0.01; Fig 2) .
The distribution of change in adherence for all 66 patients ranged from an absolute decrease in compliance of 52% to an increase of 68% (Fig 1) . In the intervention group, the adherence rate improved by at least 10% in 66% of patients (n ϭ 23/35), a significantly higher proportion than the 45% (n ϭ 14/31) in the control group (P ϭ 0.05). 
Factors Associated with Improved Adherence
In a univariate analysis, factors associated with an improved adherence rate included intervention group (P ϭ 0.01), bilateral use of medicine (P ϭ 0.04), and institution (P ϭ 0.03) ( Table 4) . Patients' attitudes and knowledge of glaucoma and their selfreported use of topical ocular hypotensive agents were not associated with improved adherence in univariate analysis (data not shown). In multivariate analysis that included the treatment, length of time on glaucoma medication, bilateral use of medication, age, race, education, baseline compliance rate, and use of travoprost without using the devise as predictors, with adherence rate change as a continuous variable, the factors that were significantly associated with improved adherence were intervention (PϽ0.01), a low baseline adherence rate (Ͻ50%, PϽ0.01), and white race (P ϭ 0.02; Table 5 ). African-Americans were less likely to have any improvement in adherence rate (60%) compared with whites (88%, P ϭ 0.02).
Intraocular Pressure and Adherence Patterns
The mean IOP did not change significantly from baseline to the end of phase 1 at 3 months, nor was it significantly different between months 3 and 6 after intervention, whether all patients were considered together or split into study groups (P ϭ 0.81). Likewise, there was no correlation between IOP change from phase 1 to phase 2 and the adherence rate change for all study eyes taken together (n ϭ 114 eyes, Pearson correlation r ϭ 0.06, P ϭ 0.51).
Intervention Assessment
For the 35 patients randomized to the intervention group, telephone calls were made at weeks 1 to 5, 7, 9, and 11. The number of patients contacted was highest at week 1 (100%), and over the remaining weeks there was a decline in the number successfully contacted (week 11, 63%). Reasons for the decline included early dropout from study, inability to contact patients, and early final visit. During weeks 6, 8, 10, and 12, the intervention patients were not called, and this did not seem to adversely affect the adherence rate for the group.
Discussion
We found that a multifaceted program for enhancing glaucoma eyedrop use improved the adherence rate from 54% to 73% (PϽ0.001) in persons whose baseline drop-taking was less than 75%. The intervention was administered completely by study staff and did not include physician input with the patient. The intervention was designed to maximize the chance that the adherence with medication use would improve. Our findings suggest that using several approaches at once likely increased the probability that the interventions changed eyedrop use. Although the strategy used in this trial clearly was effective, we cannot determine which aspects of the intervention were most valuable and which individual elements can pragmatically be implemented in clinical practice. We did not record the actual time required for the video and structured interview or determine costs for implementation of the intervention. However, our demonstration that adherence can be improved should stimulate further research into the individual components of our intervention. Although better adherence should produce lower IOP in general, improvement in adherence was not matched by lower IOP levels as measured in the clinic. This was not surprising, because we had only 3 IOP measurements, 1 at each study visit, compared with daily values for adherence. In addition, our phase 1 data 14 showed that poorly adherent patients increase drop-taking during the 2 weeks before the office visit. Thus, IOP taken during the office visit was an inadequate surrogate for estimating adherence. These findings are not unique to ophthalmology. Studies of interventions in patients with hypertension and asthma also have found improved adherence, but not necessarily improved clinical measurements at the time of office visits. 10, 11 We found previously that physicians have used the IOP level as an important measure of poor adherence. 9 A patient who is failing to achieve the IOP target needs either a change in medication or an improvement in adherence. But the current findings clearly showed that many nonadherent patients had satisfactory IOP at routine visits. Thus, better tools are needed to distinguish poor adherence from poor efficacy in patients not at target to avoid overmedication (or over-prescription with continued poor adherence to multiple drugs).
It is likely that educational efforts to improve patient drop-taking played an important role in improving patient adherence in the intervention arm. These included instruction on proper administration of eye drops, correct dosing schedules, minimization of waste of medication, and a clear discussion that vision can be lost if the medications are not used properly. Further research on the most effective methods to communicate with patients, through better physician communication, educational programs administered by office staff, video presentations, or combinations of these, is needed.
We showed that the effect of education and reminder systems could be sustained for at least 3 months. Norell 12 found a significant decrease in adherence with pilocarpine drops over the interval between visits when the education effort occurred only in the office. Use of a device alarm in the study by Laster et al 13 showed a more continuous effect over the interval in between office visits. 13 With the availability of cell phones and Internet communication, there are several potential avenues that deserve exploration to improve adherence using continuous reminder systems. 16 -18 Past studies have shown that the cost of medication and access to care are significant barriers to adherence. 19, 20 Our study eliminated both of these obstacles by providing free medication and ensuring minimal loss to follow-up among persons already able to access care. The authors speculate that adherence would be even lower among patients for whom these barriers remain in place.
Among our patients, there were 3 factors associated with greater improvement in adherence in univariate analysis: intervention, bilateral use of medicine, and attendance at the Wilmer Eye Institute Glaucoma service. Among these 3 factors, the multivariate analysis showed that only the intervention remained significantly associated with improved adherence, whereas institution and bilateral use of medicine were no longer significant and ethnicity and extremely low baseline adherence became significant. There may be substantial correlation among these variables. For example, nearly all our patients from the Scheie Eye Institute were African-derived, whereas the majority of patients from the Wilmer Eye Institute were white. Patients from the Wilmer Eye Institute had taken drops longer than those at the Scheie Eye Institute. Other factors that may play a role in associations between ethnicity and adherence, including patientphysician interaction, 21 perceived personal dissimilarity of Figure 2 . Line graph demonstrating comparison of adherence rate by group at 0 to 3 months (phase 1 before intervention) and 3 to 6 months (phase 2 after the intervention). From bottom to top: Gray thin line with triangles indicates the mean adherence rate for the nonadherent control group over 12 weeks during phase 1 from 0 to 3 months. Gray heavy line with squares indicates the mean adherence rate for the nonadherent control group over 12 weeks during phase 2 from 3 to 6 months. Black thin line with triangles indicates the mean adherence rate for the intervention group over 12 weeks during phase 1 from 0 to 3 months. Black heavy line with squares indicates the mean adherence rate for the intervention group over 12 weeks during phase 2 from 3 to 6 months.
the patient with the doctor, 22 and experiences with discrimination, 23 may also contribute to a patient's decreased intent to adhere. Further research is needed to understand more clearly what factors led African-American patients to have both lower baseline adherence 14 and lower improvement in adherence with intervention. It is possible that interventions for adherence must be tailored to the beliefs and situation of major ethnic groups.
A baseline adherence rate Ͻ50% was associated with improved adherence. It is possible that this finding is in part due to regression to the mean. However, we previously found an association between less knowledge about glaucoma treatment and low adherence (Friedman DS. Risk factors for poor adherence with eyedrops in electronically monitored glaucoma patients. Poster presented at American Glaucoma Society, March 2008, Washington, DC). This has been demonstrated in Korean hypertensive patients whose adherence was higher in those more informed about the disease. 24 It is logical that our educational efforts about the disease in the intervention eliminated some of the lack of adherence because of this factor.
Our study had some limitations. Although we used a standard randomization process, the intervention group had somewhat more veteran eyedrop takers. This may have increased the magnitude of the intervention effect, because our univariate analysis showed lower adherence among less-experienced eyedrop takers. The adherence rate of the controls increased slightly, which was most likely due to regression to the mean. This effect was small in comparison with the treatment effect in the intervention group, but if we assume the intervention group would have had a similar increase, the treatment effect is likely smaller than measured. We informed patients that they were being monitored and provided drugs at no cost. It is likely that the adherence of patients who are not in a study under these conditions would be lower at baseline and perhaps might exhibit a different intervention effect. We used an electronic device to measure adherence as the primary outcome variable. Electronic monitoring of drug-taking behavior is the most accurate method for identifying nonadherence. 14, 25, 26 Research with the DA has limitations, however, as shown by patients in this study who took their drops without placing the bottle in the devices, which in fact decreased the measured adherence rate in the intervention group, but not significantly. When excluding those who took drops without the DA, the measured adherence improved slightly in the control group, but still the difference in magnitude of improved adherence between the intervention group and the control group remained large. In addition, the findings were limited to the use of 1 prostaglandin analogue, because only its bottle fits in the device.
In conclusion, adherence with glaucoma drop use improved over a 3-month period with an intervention strategy consisting of education and reminder systems. In addition, improvement was immediate and sustained over 3 months. There was greater improvement in adherence among white patients and those with the lowest baseline adherence. IOP was a poor surrogate for monitoring adherence, probably because of increased adherence just before the visit. Further research is needed to determine which components of this intervention were most effective. SE ϭ standard error. NOTE: All the independent variables included in the multivariate model are listed above. *Three patients were excluded from the multivariate analysis because of missing value in education status (n ϭ 2) and use of travoprost without using the device during the study (n ϭ 1). Asians were also excluded because of small number (n ϭ 1). † From 1-way analysis of variance.
